F.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD

The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.

The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.

Read more

Psilocybin for Anorexia

A recent study has shed light on the potential of psilocybin, the active compound in magic mushrooms, as a promising treatment for anorexia nervosa (AN).

This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.

The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.

Read more

Psychedelics and Prolonged Grief Disorder

Psychedelics such as psilocybin and MDMA may be a promising treatment avenue for Prolonged Grief Disorder (PGD).

Randomized clinical trials demonstrated the efficacy of psilocybin in reducing symptom severity in depression and MDMA in reducing PTSD symptomatology.

Furthermore, psychedelics often produce subjective effects (such as transcendence, mystical experiences, and a sense of oneness) that may be uniquely relevant to the existential distress experienced in PGD.

Read more